CGRP receptor antagonists

A compound of the Formula I:

• wherein:
• A is a bond;
• B is (C(R2)2)n;
• R1 is selected from:
• 1) H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR4,
• i) O(CH2)s OR4,
• j) CO2R4,
• k) (CO)NR10R11,
• l) O(CO)NR10R11,
• m) N(R4)(CO)NR10R11,
• n) N(R10)(CO)R11,
• o) N(R10)(CO)OR11,
• p) SO2NR10R11,
• q) N(R10) SO2R11,
• r) S(O)mR10,
• s) CN,
• t) NR10R11,
• u) N(R10)(CO)NR4R11 and,
• v) O(CO)R4;
• 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR4,
• i) O(CH2)sOR4,
• j) CO2R4,
• k) (CO)NR10R11,
• l) O(CO)NR10R11,
• m) N(R4)(CO)NR10R11,
• n) N(R10)(CO)R11,
• o) N(R10)(CO)OR11,
• p) SO2NR10R11,
• q) N(R10) SO2R11,
• r) S(O)mR10,
• s) CN,
• t) NR10R11,
• u) N(R10)(CO)NR4R11 and,
• t) O(CO)R4;
• R2 is independently selected from:
• 1) H, C0-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR4,
• i) O(CH2)sOR4,
• j) CO2R4,
• k) (CO)NR10R11,
• l) O(CO)NR10R11,
• m) N(R4)(CO)NR10R11,
• n) N(R10)(CO)R11,
• o) N(R10)(CO)OR11,
• p) SO2NR10R11,
• q) N(R10) SO2R11,
• r) S(O)mR10,
• s) CN,
• t) NR10R11,
• u) N(R10)(CO)NR4R11 and,
• v) O(CO)R4;
• 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR4,
• i) O(CH2)sOR4,
• j) CO2R4,
• k) (CO)NR10R11,
• l) O(CO)NR10R11,
• m) N(R4)(CO)NR10R11,
• n) N(R10)(CO)R11,
• o) N(R10)(CO)OR11,
• p) SO2NR10R11,
• q) N(R10) SO2R11,
• r) S(O)mR10,
• s) CN,
• t) NR10R11,
• u) N(R10)(CO)NR4R11 and,
• v) O(CO)R4,
• or, any two independent R2 on the same or adjacent atoms may be joined together to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, morpholinyl, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl and piperazinyl;
• R10 and R11 are independently selected from:
• H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl, and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy, where R10 and R11 may be joined together to form a ring selected from:
• azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4;
• R4 is independently selected from:
• H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy;
• W is O, NR4 or C(R4)2;
• X is C or S;
• Y is O, (R4)2, NCN, NSO2CH3, NCONH2, or Y is O2 when X is S;
• R6 is independently selected from H and:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR4,
• i) O(CH2)sOR4,
• j) CO2R4,
• k) (CO)NR10R11,
• l) O(CO)NR10R11,
• m) N(R4)(CO)NR10R11,
• n) N(R10)(CO)R11,
• o) N(R10)(CO)OR11,
• p) SO2NR10R11,
• q) N(R10) SO2R11,
• r) S(O)mR10,
• s) CN,
• t) NR10R11,
• u) N(R10)(CO)NR4R11 and,
• v) O(CO)R4;
• G-J is selected from:
• N, N—C(R5)2, C═C(R5), C═N;
• C(R5), C(R5)-C(R5)2, C(R5)-C(R5)2-C(R5)2, C═C(R5)-C(R5)2, C(R5)-C(R5)═C(R5), C(R5)-C(R5)2-N(R5), C═C(R5)-N(R5), C(R5)-C(R5)=N, C(R5)-N(R5)-C(R5)2, C═N—C(R5)2, C(R5)-N═C(R5), C(R5)-N(R5)-N(R5), C═N—N(R5), N—C(R5)2-C(R5)2, N—C(R5)═C(R5), N—C(R5)2-N(R5), N—C(R5)=N, N—N(R5)-C(R5)2 and N—N═C(R5);
• Q, T, U and V are each independently carbon or nitrogen wherein at least one but no more than three of Q, T, U and V are nitrogen, of which one may be optionally an N-oxide, and wherein when any of Q, T, U, or V is carbon it is unsubstituted or substituted where the substituents are independently selected from R6;
• R5 is independently selected from H, substituted or unsubstituted C1-C3 alkyl, CN, OR4, N(R4)2 and CO2R4;
• R3 is independently selected from H, substituted or unsubstituted C1-C3 alkyl, F, CN and CO2R4;
• p is 0 to 2 q+1, for a substituent with q carbons;
• m is 0, 1 or 2;
• n is 0 or 1;
• s is 1, 2 or 3;
• wherein “heteroaryl” means a stable 5- to 7-membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, or unsaturated, and which consists of carbon atoms and from one to four heteratoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring;
• and “heterocycle” means a stable 5- to 7-membered monocyclic- or stable 8- to 11-membered bicyclic heterocyclic ring system which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteratoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring;
• or a pharmaceutically acceptable salt or individual diastereomers thereof.